Gao Liping, Zhu Chongxue, Jackson Edwin K
Center for Clinical Pharmacology, University of Pittsburgh School of Medicine, 3550 Terrace Street, Pittsburgh, PA 15261, USA. edj+@pitt.edu
J Pharmacol Exp Ther. 2003 May;305(2):581-6. doi: 10.1124/jpet.102.047647. Epub 2003 Feb 11.
Hypertension in spontaneously hypertensive rats (SHRs) is due in part to enhanced effects of vasoactive peptides on the renal vasculature. We hypothesize that the G(i) signal transduction pathway enhances renovascular responses to vasoactive peptides in SHRs more so than in normotensive Wistar-Kyoto (WKY) rats. To test this hypothesis, we examined in isolated perfused kidneys from SHRs and WKY rats the renovascular responses (assessed as changes in renal perfusion pressure in mm Hg) to angiotensin II (10 nM) and vasopressin (3 nM) in the presence and absence of UK-14,304 [5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine; an agonist that selectively activates the G(i) pathway by stimulating alpha(2)-adrenoceptors]. In SHR, but not WKY, kidneys, UK-14,304 (10 nM) enhanced (P < 0.05) renovascular responses to angiotensin II (control WKY, 43 +/- 6; UK-14,304-treated WKY, 52 +/- 19; control SHR, 66 +/- 17; UK-14,304-treated SHR, 125 +/- 16) and vasopressin (control WKY, 42 +/- 17; UK-14,304-treated WKY, 36 +/- 11; control SHR, 16 +/- 8; UK-14,304-treated SHR, 83 +/- 17). Pretreatment of SHRs with pertussis toxin (30 microg/kg, intravenously, 3-4 days before study) to inactivate G(i) blocked the effects of UK-14,304. Western blot analysis of receptor expression in whole kidney and preglomerular microvessels revealed similar levels of expression of AT(1), V(1a), and alpha(2A) receptors in SHRs compared with WKY rats. We conclude that activation of alpha(2)-adrenoceptors selectively enhances renovascular responses to angiotensin II and vasopressin in SHRs via an enhanced cross talk between the G(i) signal transduction pathway and signal transduction pathways activated by angiotensin II and vasopressin.
自发性高血压大鼠(SHR)的高血压部分归因于血管活性肽对肾血管系统的作用增强。我们假设,与正常血压的Wistar-Kyoto(WKY)大鼠相比,G(i)信号转导途径能更显著地增强SHR肾血管对血管活性肽的反应。为验证这一假设,我们在SHR和WKY大鼠的离体灌注肾脏中,检测了在存在和不存在UK-14,304 [5-溴-N-(4,5-二氢-1H-咪唑-2-基)-6-喹喔啉胺;一种通过刺激α(2)-肾上腺素能受体选择性激活G(i)途径的激动剂]的情况下,肾血管对血管紧张素II(10 nM)和加压素(3 nM)的反应(以毫米汞柱为单位的肾灌注压变化来评估)。在SHR而非WKY大鼠的肾脏中,UK-14,304(10 nM)增强了(P < 0.05)肾血管对血管紧张素II的反应(对照WKY,43±6;UK-14,304处理的WKY,52±19;对照SHR,66±17;UK-1,304处理的SHR,125±16)以及对加压素的反应(对照WKY,42±17;UK-14,304处理的WKY,36±11;对照SHR,16±8;UK-14,304处理的SHR,83±17)。在研究前3至4天,用百日咳毒素(30微克/千克,静脉注射)预处理SHR以灭活G(i),可阻断UK-14,304的作用。对整个肾脏和肾小球前微血管中受体表达的蛋白质印迹分析显示,与WKY大鼠相比,SHR中AT(1)、V(1a)和α(2A)受体的表达水平相似。我们得出结论,α(2)-肾上腺素能受体的激活通过增强G(i)信号转导途径与血管紧张素II和加压素激活的信号转导途径之间的相互作用,选择性地增强了SHR肾血管对血管紧张素II和加压素的反应。